aibioDyadic International gets Nasdaq deficiency notice under Rule 5550(b) minimum listing requirements
Tickers DYAI
Dyadic received a Nasdaq notice on March 27, 2026 that it is out of compliance with Listing Rule 5550(b). It has until May 11, 2026 to submit a plan to regain compliance, and a separate bid price deadline of June 17, 2026 also stands.
Key facts
- Company
- Dyadic International, Inc. (NASDAQ: DYAI)
- News type
- Listings
- Primary source
- DYADIC INTERNATIONAL INC Form 8-K filed March 30, 2026 (SEC EDGAR)
Dyadic International, Inc. (Nasdaq: DYAI) said in a Form 8-K that it received a Nasdaq deficiency notice on March 27, 2026. The Nasdaq Listing Qualifications staff told the company that it is out of compliance with the technical minimum requirements for continued listing under Nasdaq Listing Rule 5550(b). The notice has no immediate effect on the listing of the common stock on the Nasdaq Capital Market.
What the rule requires
Nasdaq Listing Rule 5550(b) requires the company to maintain at least one of three measures: $2.5 million in stockholders' equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.
The deadlines
Dyadic has 45 calendar days, or until May 11, 2026, to submit a plan to regain compliance with any of the three requirements. If Nasdaq accepts the plan, the company may be eligible for a cure period of up to 180 days from March 27, 2026, which the 8-K gives as September 23, 2026. If Nasdaq does not accept the plan, Dyadic may appeal to a hearings panel under Nasdaq's listing rules. The company says there can be no assurance that an appeal would succeed.
Dyadic says it intends to monitor its compliance on an ongoing basis and to evaluate options to resolve the deficiency, likely through the $2.5 million stockholders' equity requirement.
A second deficiency
The 8-K also says Dyadic remains out of compliance with the $1.00 minimum bid price under Nasdaq Listing Rule 5550(a)(2). It has until June 17, 2026 to regain compliance with that rule, according to its earlier disclosure. A bid price deficiency means the stock has traded below the minimum price Nasdaq sets for continued listing. The company says the Rule 5550(b) deficiency is separate, and that either deficiency, if not cured by its deadline, could be a basis for delisting. The two clocks run on different dates: May 11 for the plan and June 17 for the bid price.
Losses and cash
The company's 10-K, filed March 25, 2026, reports revenue of $3.1 million for 2025, down from $3.5 million for 2024. It reports a net loss of $7.4 million for 2025, against $5.8 million for 2024. Cash used in operations was $5.7 million in 2025 and $4.0 million in 2024. The 10-K says cash, cash equivalents and restricted cash were $5,853,000 as of December 31, 2025, compared with $6,507,000 a year earlier.
The 10-K's risk factors list the company's history of net losses and its need for sufficient additional capital to continue as a going concern. It also says a significant portion of its revenue comes from a small number of customers.
The business
Dyadic describes itself as a global biotechnology company doing business as Dyadic Applied BioSolutions, based in Jupiter, Florida, with a satellite office in the Netherlands. It develops, manufactures and commercializes animal-free recombinant proteins and enzymes for life sciences, food and nutrition, and bio-industrial applications, produced on its microbial expression platforms, including the C1 and Dapibus systems. Its commercial strategy includes direct product sales, distribution partnerships, manufacturing collaborations and technology licensing agreements.
The C1 platform is based on the fungus Thermothelomyces heterothallica. Dyadic licensed it to third parties for industrial uses, including Abengoa Bioenergy, BASF SE and Codexis, Inc. After selling certain industrial technology assets to Danisco USA, it kept rights to sublicense the C1 platform for human and animal pharmaceutical applications.
Who signed
Chief Financial Officer Ping Rawson signed the 8-K.